Baltimore, MD – According to filings with the U.S. Securities and Exchange Commission, Glyscend is raising $20,875,047.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Ashish Nimgaonkar played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Glyscend

Glyscend is dedicated to the development of a revolutionary approach to treating metabolic diseases. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia.

To learn more about Glyscend, visit http://www.glyscend.com/

Contact:
Ashish Nimgaonkar, President and Chief Executive Officer
443-961-2147
https://www.linkedin.com/in/ashish-nimgaonkar-md-66322915/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved